Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia
Crossref DOI link: https://doi.org/10.1007/s00508-015-0789-4
Published Online: 2015-05-19
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Amann, Arno
Steiner, Normann
Gunsilius, Eberhard
Text and Data Mining valid from 2015-05-19
